苯胺基乙腈 | 3009-97-0

• 物质功能分类: 化学试剂 - 有机试剂 - 氰化物/腈
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 苯胺基乙腈
• 中文别名: N-苯基甘油乙腈
• 英文名称: N-phenylglycinonitrile
• 英文别名: 2-(phenylamino)acetonitrile；anilinoacetonitrile；N-(cyanomethyl)-aniline；2-anilinoacetonitrile
• CAS: 3009-97-0
• 化学式: C₈H₈N₂
• mdl: MFCD00044430
• 分子量: 132.165
• InChiKey: KAXCEFLQAYFJKV-UHFFFAOYSA-N

物化性质

• 熔点：
  40 °C
• 沸点：
  234.08°C (rough estimate)
• 密度：
  1.1083 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 稳定性/保质期：
  避免与不相容材料接触，特别是强氧化剂。

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S36/37
• 危险类别码：
  R20/21/22
• 海关编码：
  2926909090
• WGK Germany：
  3
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  密封储存，应存放在阴凉、干燥的仓库中。

SDS

Name:	N-Phenylglycinonitrile 97% Material Safety Data Sheet
Synonym:	1-Anilinoacetonitrile; Acetonitrile, anilino-; Acetonitrile, phenylamino-; Anilinoacetonitrile; N-(Cyanomethyl)aniline; Phenylglycine nitril
CAS:	3009-97-0

Section 1 - Chemical Product MSDS Name:N-Phenylglycinonitrile 97% Material Safety Data Sheet
Synonym:1-Anilinoacetonitrile; Acetonitrile, anilino-; Acetonitrile, phenylamino-; Anilinoacetonitrile; N-(Cyanomethyl)aniline; Phenylglycine nitril

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3009-97-0	N-Phenylglycinonitrile	97	221-129-0

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. Metabolism may release cyanide, which may result in headache, dizziness, weakness, collapse, unconsciousness and possible death.
Inhalation:
May cause respiratory tract irritation. May be metabolized to cyanide which in turns act by inhibiting cytochrome oxidase impairing cellular respiration.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3009-97-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 40 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C8H8N2
Molecular Weight: 132.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3009-97-0: AM1750000 LD50/LC50:
Not available.
Carcinogenicity:
N-Phenylglycinonitrile - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 3009-97-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3009-97-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3009-97-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：土黄色或黄褐色固体，相对密度在10℃时为1.200 kg/m³，熔点为40℃。

用途：苯胺基乙腈是生产靛蓝的中间体，主要用于牛仔布染色，也用作染料中间体。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  N-甲基苯胺	N-methylaniline	100-61-8	C7H9N	107.155
  N-苯基甘氨酸	N-Phenylglycine	103-01-5	C8H9NO2	151.165
  N-苯基甲酰胺	Formanilid	103-70-8	C7H7NO	121.139

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  N-乙基苯胺	N-ethyl-N-phenylamine	103-69-5	C8H11N	121.182
  N-苯基乙二胺	N-(2-aminoethyl)benzeneamine	1664-40-0	C8H12N2	136.197
  2-(氰基甲基-苯基-氨基)乙腈	N-phenyl-N,N-bis(cyanomethyl)amine	86273-74-7	C10H9N3	171.202
  N-戊基苯胺	N-pentylaniline	2655-27-8	C11H17N	163.263
  N-甲基苯胺	N-methylaniline	100-61-8	C7H9N	107.155
  ——	N-(3-methylbut-2-enyl)aniline	27125-60-6	C11H15N	161.247
  ——	bis(2-phenylaminoethyl)amine	4432-90-0	C16H21N3	255.363
  2-苯胺乙酰胺	2-anilinoacetamide	21969-70-0	C8H10N2O	150.18
  ——	2-(phenylamino)ethanethioamide	18138-16-4	C8H10N2S	166.247
  N-苯基甘氨酸	N-Phenylglycine	103-01-5	C8H9NO2	151.165

反应信息

• 作为反应物：
  描述：

  苯胺基乙腈 在 水 作用下， 以 aq. phosphate buffer 为溶剂， 生成 N-苯基甘氨酸
  参考文献：
  名称：

  为生物催化应用扩展具有广泛底物特异性和高底物耐受性的腈水解酶库

  摘要：

  摘要 腈水解酶将腈酶促转化为羧酸在多种药物前体和精细化学品的绿色合成中具有重要意义。尽管已经对来自多种来源的腈水解酶进行了表征，但仍存在确定表现出更高底物耐受性和更好热稳定性的广谱腈水解酶以开发工业相关生物催化过程的范围。通过基因组挖掘，我们从细菌中鉴定了 9 种新型腈水解酶序列，并评估了它们对 23 种工业相关腈底物的广谱活性。来自 Zobellia galactanivorans、Achromobacter insolitus 和 Cupriavidus necator 的腈水解酶对不同种类的腈具有高度活性，并在实验室规模的过程中用作全细胞生物催化剂。Z。galactanivorans 腈水解酶可以通过补料分批添加底物在 3 小时内转化 4-氰基吡啶以达到 1.79 M 异烟酸的产量。来自 A. insolitus 的腈水解酶可以快速水解 630 mM 亚氨基二乙腈，在 1 小时内将 86%

  DOI：

  10.1016/j.procbio.2020.05.004
• 作为产物：
  描述：

  六氢-1,3,5-三苯基-1,3,5-三嗪 在 sodium hydrogensulfite 作用下， 生成 苯胺基乙腈
  参考文献：
  名称：

  Bucherer; Schwalbe, Chemische Berichte, 1906, vol. 39, p. 2801

  摘要：

  DOI：

文献信息

• Heterobicyclic pyrazole compounds and methods of use
  申请人：Blake F. James

  公开号：US20070238726A1

  公开（公告）日：2007-10-11

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。公开了使用化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐的方法，用于体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理条件。
• [EN] METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS<br/>[FR] METHODES ET COMPOSITIONS A BASE DE NOUVEAUX COMPOSES DE TRIAZINE
  申请人：REDDY US THERAPEUTICS INC

  公开号：WO2004026844A1

  公开（公告）日：2004-04-01

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状况的化合物的方法和组合物。特别是，本发明涉及抑制或阻断在内皮细胞中由糖化蛋白产生的与信号传递相关的炎症反应的化合物。本发明还涉及抑制平滑肌细胞增殖的化合物。特别是，本发明涉及通过调节诸如Perlecan的HSPGs来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物来治疗由平滑肌增殖特征的心血管闭塞性状况，如再狭窄和动脉粥样硬化。
• Methods and compositions of novel triazine compounds
  申请人：——

  公开号：US20040224950A1

  公开（公告）日：2004-11-11

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状况的化合物的方法和组合物。特别是，本发明旨在使用化合物来抑制或阻断在内皮细胞中由糖化蛋白产生的与信号传导相关的炎症反应。本发明还涉及抑制平滑肌增殖的化合物。特别是，本发明旨在使用通过调节如Perlecan之类的HSPGs来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物来治疗由平滑肌增殖特征的心血管闭塞性状况，如再狭窄和动脉粥样硬化。
• Substituted quinazoline derivatives and their use as inhibitors
  申请人：AstraZeneca AB

  公开号：US20030187002A1

  公开（公告）日：2003-10-02

  The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O) 2 , or NR 6 where R 6 is hydrogen or C 1-6 alkyl,; R 5 is an optionally substituted 5-membered heteroaromatic ring, R 1 , R 2 , R 3 , R 4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed.

  使用式(I)的化合物或其盐、酯或酰胺； 其中X为O、S、S(O)或S(O)2，或NR6，其中R6为氢或C1-6烷基； R5为可选择取代的5-成员杂芳环， R1、R2、R3、R4分别选自各种指定的基团，在制备用于抑制aurora 2激酶的药物中使用。 某些化合物是新颖的，这些化合物以及含有它们的药物组合物也有描述和声明。
• Dynamics in Catalytic Asymmetric Diastereoconvergent (3 + 2) Cycloadditions with Isomerizable Nitrones and α-Keto Ester Enolates
  作者：Tetsuya Ezawa、Yoshihiro Sohtome、Daisuke Hashizume、Masaya Adachi、Mai Akakabe、Hiroyuki Koshino、Mikiko Sodeoka

  DOI：10.1021/jacs.1c02833

  日期：2021.6.23

  Reaction design in asymmetric catalysis has traditionally been predicated on a structurally robust scaffold in both substrates and catalysts, to reduce the number of possible diastereomeric transition states. Herein, we present the stereochemical dynamics in the Ni(II)-catalyzed diastereoconvergent (3 + 2) cycloadditions of isomerizable nitrile-conjugated nitrones with α-keto ester enolates. Even in

  传统上，不对称催化中的反应设计基于底物和催化剂中结构坚固的支架，以减少可能的非对映异构过渡态的数量。在此，我们展示了 Ni(II) 催化的非对映会聚 (3 + 2) 环加成反应中的可异构化腈共轭硝酮与 α-酮酯烯醇化物的立体化学动力学。即使在存在多个平衡物种的情况下，催化协议也显示出广泛的底物范围，以访问一系列带有相邻立体中心的含 CN 构建块，具有高对映选择性和非对映选择性。我们的计算研究表明，在去质子化过程中形成 ( Z )-Ni-烯醇化物的过程中控制了对映选择性，而独特的合成 添加主要由硝酮和配体之间的弱非共价键相互作用控制。